Abstract
Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin
| Original language | English (US) |
|---|---|
| Pages (from-to) | 409-417 |
| Number of pages | 9 |
| Journal | Oncologist |
| Volume | 11 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2006 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia'. Together they form a unique fingerprint.
Cite this
Boccia, R., Malik, I. A., Raja, V., Kahanic, S., Liu, R., Lillie, T., Tomita, D., Clowney, B., & Silberstein, P. (2006). Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist, 11(4), 409-417. https://doi.org/10.1634/theoncologist.11-4-409